- Home
- ALLO
as of 12-09-2025 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 252.9M | IPO Year: | 2018 |
| Target Price: | $8.67 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $3.78 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | -76.84% |
| Revenue Growth (this year): | -42.05% | Revenue Growth (next year): | 100.00% |
AI-Powered ALLO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
SVP, Chief Technical Officer
Avg Cost/Share
$1.22
Shares
786
Total Value
$958.92
Owned After
217,721
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$1.26
Shares
36,744
Total Value
$46,168.84
Owned After
1,276,796
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Nov 17, 2025 | Sell | $1.22 | 786 | $958.92 | 217,721 | |
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Oct 21, 2025 | Sell | $1.26 | 36,744 | $46,168.84 | 1,276,796 |
Compare ALLO vs Leading Stocks
See how ALLO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.